Who
Keith L. Brownlie
Director
Company insider
Files Form 4 as: Director, Celldex Therapeutics; Director, Phio Pharmaceuticals; Director, Soligenix; Director, Cancer Genetics; Director, Epicept.
In numbers
- Trades disclosed
- 42
- Buys
- 1
- Sells
- 0
- Bought
- $20K
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 5
- First trade
- 27 Apr 2011
- Last trade
- 25 Jun 2026
- Last filed
- 29 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Jun 2026filed 29 Jun 2026 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —26,000 at $0.00 | filing |
| 25 Jun 2026filed 29 Jun 2026 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —26,000 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —16,500 at $0.00 | filing |
| 13 Jun 2024filed 17 Jun 2024 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —16,500 at $0.00 | filing |
| 15 Jun 2023filed 20 Jun 2023 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —11,300 at $0.00 | filing |
| 16 Jun 2022filed 17 Jun 2022 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —13,600 at $0.00 | filing |
| 17 Jun 2021filed 21 Jun 2021 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 18 Jun 2020filed 19 Jun 2020 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —11,000 at $0.00 | filing |
| 19 Jun 2019filed 20 Jun 2019 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —4,500 at $0.00 | filing |
| 13 Feb 2019filed 15 Feb 2019 | PHIO Phio PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 27 Sep 2018filed 28 Sep 2018 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,964 at $0.00 | filing |
| 1 Aug 2018filed 3 Aug 2018 | PHIO Phio PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 13 Jun 2018filed 15 Jun 2018 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —67,000 at $0.00 | filing |
| 15 Jun 2017filed 16 Jun 2017 | CLDX Celldex TherapeuticsDiagnostics & Labs | SEC FORM 4 Code A | —10,000 | filing |
| 15 Jun 2017filed 16 Jun 2017 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —15,000 at $0.00 | filing |
| 15 Jun 2017filed 16 Jun 2017 | CLDX Celldex Therapeuticsoption or derivative · Diagnostics & Labs | SEC FORM 4 Code A | —8,000 at $0.00 | filing |
| 8 Jun 2017filed 12 Jun 2017 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —13,100 at $0.00 | filing |
| 1 Feb 2017filed 3 Feb 2017 | PHIO Phio Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,000 at $0.00 | filing |
| 16 Jun 2016filed 20 Jun 2016 | SNGX Soligenixoption or derivative · Biotechnology | SEC FORM 4 Code A | —40,541 at $0.00 | filing |
| 10 Feb 2016filed 12 Feb 2016 | PHIO Phio Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,666 at $0.00 | filing |
News
Reviewing Soligenix (NASDAQ:SNGX) and Curis (NASDAQ:CRIS)SNGX · themarketsdaily.com · 17 Oct 2026
0 headlines in the last 90 days name Keith L. Brownlie; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.